The very high binding affinity of avidin to biotin is one of the highest to occur in nature. We constructed a fusion protein composed of avidin and the endocytotic LDL receptor in order to target biotinylated molecules to cells of the desired tissues. In addition to the native avidin, charge-mutated and nonglycosylated avidins were utilized as part of the fusion proteins, in order to modify its properties. All of the fusion protein versions retained the biotin-binding capacity. Although the specificity was not increased, however, fusion proteins composed of natural avidin and nonglycosylated avidin bound most efficiently to the biotinylated ligands. Fluorescence microscopy and atomic force microscopy studies revealed the expression of the fusion protein on cell membranes, and demonstrated specific and high-affinity binding of biotin to the low-density lipoprotein receptor (LDLR)-avidin fusion protein in vitro. Additionally, systemically administered biotinylated ligand targeted with high specificity the intracerebral tumors of rats that were expressing fusion protein after the virus-mediated gene transfer. These results suggest that local gene transfer of the fusion protein to target tissues may offer a novel tool for the delivery of biotinylated molecules in vitro and in vivo for therapeutic and imaging purposes.
Introduction
Several therapeutic approaches to treat cancer are limited in their success, because of the lack of specificity of the drugs used for the therapy. The therapeutic index of several cytotoxic drugs is very narrow, which limits the possibility to reach effective tissue concentrations. Therefore, the ability to direct a cytotoxic compound to a particular class of target cells is a major task, and will be important not only to achieve a therapeutic effect but also in the limitation of potential adverse effects. One approach to increase the efficiency and specificity is to utilize the avidin-biotin technology. The wide use of the technology in many diagnostic, biological, pharmacological and therapeutical applications [1] [2] [3] [4] is based on the exceptionally high affinity of avidin to biotin (dissociation constant K d ¼10 À15 M). 5 This strong avidin-biotin interaction can be used to develop targeted therapies in eliciting a selective biological effect on specific cells or tissues, while minimizing side effects in other organs. Additionally, biotin itself can be combined to almost any type of molecules through its valeric acid chain, without affecting the biological properties of the molecule. Recent results from avidin-based targeting of drugs and imaging agents in vivo have been encouraging. 3, [6] [7] [8] [9] [10] [11] In multistep pretargeting applications, avidin has been used as a fusion protein with an antibody, 3 as a linker between biotinylated antibody and biotinylated radionuclide, 12 as well as a carrier to remove free biotinylated antibodies. 13 In this study, the strong biotin-binding capacity of avidin is utilized in the low-density lipoprotein receptor (LDLR)-avidin fusion protein. These are composed of the sequence of the endocytotic LDLR 14 and avidin. Additionally, modifications of avidin in order to improve physicochemical properties of the fusion properties have been explored. We showed the functionality of the fusion proteins in vitro and in vivo using the Semliki Forest Virus (SFV) expression system. The LDLR-avidin fusion proteins represent a potential new tool to achieve the targeted delivery of biotinylated ligands for local drug therapy and diagnostic applications.
Results
The LDLR-avidin fusion proteins are expressed in cells in multimeric forms
The fusion proteins were designed to target biotinylated molecules to desired tissues ( Figure 1) . The cytoplasmic domain, the transmembrane domain and part of the EGF-homology domain of the LDLR were selected to compose the major part of the fusion protein. Avidin, which permits targeted binding of the biotinylated ligands, is located extracellularly at the N-terminus of the fusion protein. Table 1 describes four versions of the fusion proteins, which were generated for this study. In addition to native avidin, three versions of the fusion proteins mutated in the avidin domain were designed to reduce nonspecific binding to cell surface and matrix components: (i) NgAvm-fusion protein (nonglycosylated, avidin mutation; N17I), (ii) Avm-pI4.7-fusion protein (reduced pIB4.7, mutations; R2A, K3E, K9E, R26N, R59A, R124A) and (iii) NgAvm-pI4.7-fusion protein (nonglycosylated and pIB4.7, composed of mutations described in (i) and (ii). The LDLR moiety was similar in all fusion proteins.
SDS-PAGE and immunoblotting of the SFV-transduced cells revealed that the molecular weight of Avfusion protein monomer was 65 kDa (Figure 2a) , which is in close agreement with the calculated molecular weight of nonglycosylated monomeric fusion protein (55 kDa). Sizes of the mutated fusion proteins were 63 kDa for NgAvm-fusion protein, 67 kDa for Avm-pI4.7-fusion protein and 65 kDa for NgAvm-pI4.7-fusion protein (data not shown). Small differences in molecular weights are probably due to differences in glycosylation; NgAvmfusion protein and Ng/Avm-pI4.7-fusion protein have slightly smaller molecular weights than their fully glycosylated counterparts. Also, changes in migration Targeting of biotinylated compounds P Lehtolainen et al between Av-fusion protein and nonglycosylated fusion proteins were seen when compared to the pI mutants. This was probably due to the extensive differences in charge. SDS-PAGE analysis of acetylated samples suggested that the LDLR-avidin fusion proteins favor tetrameric conformation (Figure 2a ). Oligomerization stages of these fusion proteins were investigated by crosslinking cell lysates using bis-succinimidylsuberate as an irreversible crosslinking agent. The crosslinking experiments confirmed that the fusion protein was mainly a tetramer (B260 kDa), and to a lesser extent a monomer (B65 kDa) or a trimer (B195 kDa) (Figure 2a) . Also, NgAvm-fusion protein was mainly in a tetrameric form, while the relative amount of monomers as compared to the oligomers was higher in the pI mutants (data not shown).
In order to study synthesis and degradation of the LDLR-avidin fusion proteins, SFV-infected cells were pulse labelled with [ 
The LDLR-avidin fusion proteins were located on the cell surface and in vesicular fractions
The intracellular localization of the fusion proteins was determined using subcellular fractionation of BHK cells expressing the fusion protein, and with fluorescence and electron microscopy. BHK cells expressing the fusion protein were fractionated in 20% Percoll gradient ( Figure  3 ). SDS-PAGE analysis from the pooled samples showed that most of the fusion protein was found in the light fractions resembling the early and late endosomes ( Figure 3a ). Very little fusion protein was found in dense lysosomal fractions and middle fractions resembling ER. No differences were seen in Percoll fractionation studies between the mutated versions of the fusion protein and the unmodified version of the fusion protein (data not shown). In addition, immunoelectron microscopy studies confirmed the localization of the fusion protein on the cell surface after incubation with anti-avidin antibody labelled by 10 nm protein A-gold particles (data not shown).
Specific binding of biotin by the LDLR-avidin fusion protein was detected with fluorescence microscopy and atomic force microscopy (AFM)
The fusion protein was abundantly expressed in the SFVtransduced cells (Figure 4a ). All of the fusion protein versions retained their capacity to bind biotin. Av-and NgAvm-fusion protein bound biotin efficiently ( Figure  4b ,c), whereas with the pI mutants (Avm-pI4.7-and NgAvm-pI4.7-fusion protein) the biotin-binding capacity was significantly reduced (Figure 4d,e) . The results were in agreement with the measurements performed with AFM, which revealed a very high-affinity binding of fluorescein biotin by Av-and NgAvm-fusion protein ( Figure 5 ) on living cell membranes. No unspecific highaffinity binding of the biotin-coated probes to untransduced control cells was detected by using the AFM technique. Fewer binding events to the biotinylated probe were detected in the pI-mutated versions (Avm-pI4.7-fusion protein and NgAvm-pI4.7-fusion protein) as compared to Av-and NgAvm-fusion protein.
Systemically delivered biotinylated ligand targeted into the rat cerebral tumor expressing LDLR-avidin fusion protein
To analyze if the fusion protein was expressed and capable of ligand binding in vivo, rat malignant glioma tumors were transduced with SFVs containing Av-fusion protein. Av-fusion protein was selected for further studies because of its high biotin-binding capability in vitro as compared to its pI-mutated counterparts (AvmpI4.7-and NgAvm-pI4.7-fusion protein). The expression of the fusion protein could be detected in malignant glioma tumors near the virus injection sites (Figure 6a,b) . In addition, in close proximity to the fusion protein, expression site binding of biotinylated -horseradish Targeting of biotinylated compounds P Lehtolainen et al peroxidase (HRP) (Figure 6c,d ) was detected. No antiavidin reactivity or specific binding of biotinylated HRP was found in the control animals that did not express fusion protein (Figure 6e,f) . In order to further analyze the ability of the low-density lipoprotein-avidin fusion protein to target biotinylated ligands in vivo, biotinylated transferrin was delivered systemically via carotid artery into tumor-bearing rats (Figure 6g-i) . After the delivery, clearly higher accumulation of the ligand was found in the glioma at the site of the fusion protein expression (Figure 6h,g ) than in the control animals that received the ligand but did not express the Av-fusion protein (Figure 6j,k) .
Discussion
The approach of targeting ligands, such as cytotoxins, via a fusion protein has been of interest for the past 15 years.
The majority of these therapeutical approaches have been against cancer. 15 These studies support the hypothesis that fusion proteins can specifically target ligands, such as cytokines, or imaging agents to the tumor microenvironment. 16, 17 In this study, we generated a fusion protein that was composed of avidin and a transmembranic LDLR, in order to achieve highaffinity binding of biotinylated ligands in the target tissues. This approach may become a valuable tool for targeted drug delivery and imaging applications in vivo. Several in vivo studies have shown promising results using avidin and streptavidin-directed biotinylated monoclonal antibodies. 2, 3, 7, 18 These studies have shown that avidin-biotin-based therapies are generally well tolerated, and that they facilitate targeting of therapeutic or diagnostic compounds in experimental animals and in man. [19] [20] [21] [22] [23] Pretargeting strategies based on antibodyavidin/streptavidin conjugates have been designed to improve the target/nontarget ratio, and clinical trials have already been performed in glioma patients without significant toxicity. 20, 24, 25 However, the pretargeting system involves the administration of a targeting agent (e.g. an antibody that recognizes a specific molecule on tumor cells) before administration of the actual effector molecule, and is therefore very much dependent on the affinity and specificity of the primary targeting antibody.
In this study, we generated fusion proteins that are expressed on the surface of cell membranes and capable of high-affinity binding of biotinylated molecules. Novel fusion protein systems, such as the LDLR-avidin fusion proteins, offer a way to omit engineering of unique chimeric antibodies for each specific application or tumor type and reducing side effects due to crossreactivity of the antibodies with epitopes in healthy tissues. With the fusion protein system, only two steps are required: (i) gene transfer of the fusion protein into the target tissue and (ii) a biotinylated drug. Elimination of the antibody step by using the fusion protein gene transfer enhances the possibility of a targeted therapeutic effect. Also, the fusion protein expression system is applicable to any type of tumor.
Utilization of the transmembrane protein capable of binding biotin with high affinity offers the possibility of using a broad spectrum of biotinylated molecules both in in vivo marking trials and in the treatment of various diseases, such as cancer, vascular diseases and inflammatory diseases. This would be achieved by local gene transfer of the target tissue with the fusion protein, followed by i.v. administration of a biotinylated drug. With the fusion proteins, a systemic biotinylated drug could avoid a rapid clearance when bound to the transmembranic receptor. Since the positive charge and sugars of avidin can cause unspecific binding to matrix components, 26 three mutated versions of the fusion protein were generated, that is, NgAvm-fusion protein, Avm-pI4.7-fusion protein and NgAvm-pI4.7-fusion protein.
In vitro studies demonstrated that the fusion proteins bound fluorescein biotin with high affinity. In contrast to Av-and NgAvm-fusion protein, pI-mutated fusion proteins showed a reduced biotin-binding capacity according to fluorescence microscopy and AFM. The LDLR-avidin fusion protein and its three mutated counterparts were found primarily as multimers, the tetrameric form of which was the favored conformation. 
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Metabolic labelling experiments showed that, in BHK cells, all the four versions of the fusion protein were stable for at least 11 h after the synthesis. Tetramerization of the fusion protein might be a stabilizing factor, as it is with avidin. 27 The oligomerization state of the fusion protein is of interest because it may greatly influence the biotin-binding affinity. For tetrameric avidin, the K d is B10
À15 (M), whereas for the monomeric avidin the affinity is greatly reduced (K d B10
À7
-10 À8 M). An increase in the relative amount of the monomeric form in Avm-and NgAvm-pI4.7-fusion protein could explain why the pI mutants did not bind fluorescein biotin as efficiently as the nonmutated or NgAvm-fusion protein.
The favor of avidin for tetramerization as part of the fusion protein has been previously seen with a transmembranic scavidin protein, which was composed of the scavenger receptor moiety and avidin. 28 In scavidin, it was anticipated that fusion protein forms trimers due to native characteristics of the trimeric scavenger receptor. 29 Instead, in crosslinking studies, the strongest signal was from a tetrameric form of the fusion protein. These results indicate that the avidin moiety remains soluble, and is capable of forming multimers, such as tetramers, even when attached to the scavenger receptor or LDLR. Even though the in vitro studies did not show any significant differences in the unspecific binding of different forms of the fusion proteins, they may have improved properties over scavidin, regarding the reduced unspecific binding in vivo to matrix components via the nonglycosylated avidin moiety.
The in vivo studies demonstrated that Av-fusion protein expressed in rat malignant glioma cells was able to bind biotinylated molecules administered either locally to the brain, or systemically into the right carotid artery. Av-fusion protein was expressed near the gene transfer injection site in rat malignant glioma tumor in the same areas, where biotinylated-HRP binding or biotinylated-transferrin binding was found. This suggests that Av-fusion protein is a promising candidate for in vivo targeting. Charge-mutated versions of the fusion protein showed reduced biotin-binding capability in vitro, and were therefore not selected for in vivo studies.
In summary, we have demonstrated the high-affinity binding of biotinylated molecules to the LDLR-avidin fusion protein in vitro and in vivo. The LDLR-avidin fusion proteins are promising new tools for the targeting of therapeutic compounds, offering the possibility of enhanced local effect and a decreased systemic exposure to therapeutic compounds. Targeting of biotinylated compounds P Lehtolainen et al
Material and methods
Cloning of the LDLR-avidin fusion proteins (Lodavin) and construction of recombinant SFV-polymerase chain reaction (PCR) technique was used to amplify sequences from avidin and LDLR. Unmodified avidin and three modified avidins 26 were amplified (see Table 1 for details of the modifications) and cloned to the 5 0 end of the human LDLR 14 Four different versions of avidin cDNA (Table 1) were amplified using the following primers: PCR for Av-and Avm-pI4.7-fusion protein: 5 0 -ACCGTGGATCCCCACC TGCTGCAGAGATGGTGCACGCAACCTCCCCGC-3 0 (forward) and 5 0 -CCTCAAGATCTCTGTGTGCGCAGG CGAGTG-3 0 (reverse). PCR for NgAvm-fusion protein and NgAvm-pI4.7-fusion protein: the forward primer was the same as for Av-and Avm-pI4.7-fusion protein and 5 0 -CCTCAAGATCTCTGTGTGGCCAGGGCAGT GAAGATGTTGATGCCGA-3 0 (reverse). Avidin cDNA and LDLR were cloned to pFastBAC1 donor vector (Invitrogen), and then subcloned to the SFV expression vector (pSFV1). The nucleotide sequences of the fusion proteins were confirmed by automated DNA sequencing (A.L.F. DNA Sequenator, Amersham Biosciences, Inc.).
SFV transduction in vitro
Production of the SFV via in vitro transcription was carried out as described previously. 30 Baby hamster kidney (BHK, ATCC CCL-10) cells were maintained in BHK-21 medium (GibgoBRL) and BT4C rat glioma cells in 10% FBS/DMEM (Gibco BRL). For the SFV transductions, cells were grown on coverslips to subconfluency at 371C in 5% CO 2 . Diluted virus (1:3; Av-fusion protein, NgAvm-fusion protein, Avm-pI4.7-fusion protein, NgAvm-pI4.7-fusion protein) in PBS was added to the cells for 1 h. Virus was removed, cells were washed with 1 Â PBS and incubated for 3-5 h before analysis (i.e. Western blot, biotin binding, etc).
Western blot and crosslinking studies
Isolated protein (100 mg) from SFV-transduced cells was run in reducing 8.5% SDS-PAGE, and blotted onto a nitrocellulose membrane (1 h, 100 V, 160 mA). Membranes were blocked (5% milk powder/Tris-buffered saline, 1 h), washed and incubated for 1 h with a polyclonal antiavidin antibody (Sigma, 1:4000), and then with HRP (1:3000)-conjugated second antibody. Chemiluminescence was used for signal detection (SuperSignalt Substrate, Pierce). A sample of proteins was acetylated in situ prior to SDS-PAGE, 31 in order to detect higher order oligomers under nondenaturing conditions. 28 Supernatants were subjected to SDS-PAGE without boiling (nondenaturing conditions). A boiled sample (5 min) was used as an acetylation control (i.e. denaturing conditions). Crosslinking was performed with disuccinimidyl suberate (1 mg/ml in PBS, Pierce) for 1 h in SFV-transduced cells. Cells were lysed in 1% Triton X-100; supernatants were separated by centrifugation (25 000 g, 10 min) and subjected to 8.5% SDS-PAGE. Signal was detected as above.
Metabolic labelling
Cells transduced with SFV were depleted of methionine by incubation in a methionine-free modified Eagle's medium, pulse labelled for 30 min with [ 35 S]-Met-Cys (500 mCi/ml) medium (ICN Biologicals) and chased for 0.5-11 h. The proteins were harvested by lysis on ice, immunoprecipitated at 41C with the anti-avidin antibody in 20% BSA overnight and collected with protein A-sepharose (Pharmacia LKB Biotechnology Oy, Espoo, Finland). Proteins were dissociated from sepharose at 1001C for 5 min and run in 5-15% gradient SDS-PAGE gel.
Percoll fractionation
In order to separate lysosomes from endosomes and early endosomes (EE) from late endosomes (LE), 20% Percoll gradient was used for cell fractionation. 28, 32 Briefly, HRP (2 mg/ml) was added to the culture medium for 5 min after 4 h of fusion protein production in SFV-transduced cells. Postnuclear supernatant was prepared and mixed with a homogenate buffer containing Percoll (27%) in 0.25 M sucrose and BSA. This mixture was layered on top of 1 ml of 2.5 M sucrose cushion and centrifuged (30 000 g, 2 h). Samples were fractionated beginning from the bottom, and b-hexosaminidase (present in lysosomes and to a lesser extent in late endosomes) was assayed with p-nitrophenyl-N-acetyl-b-D-glucosaminide 32 and endocytosed HRP (present in early endosomes), with o-dianisidine as a substrate. 33 The pooled samples treated with 1% Triton X-100 (30 min on ice) were boiled for 5 min and run in 8.5% SDS-PAGE gel. Signal was detected with rabbit anti-avidin antibody and anti-rabbit-HRP conjugate (BioRad) by chemiluminescence.
Atomic force microscopy
For AFM, SFV-transduced BHK-cells were analyzed 5 h post-transduction in a serum-free, prewarmed (371C) DMEM supplemented with 20 mM HEPES. The force measurements and AFM imaging were performed with a Topometrix Explorer Tm AFM fitted with a specially constructed holder on a Nikon inverted microscope, using a 10 mm liquid scanner and silicon nitride cantilevers, as previously described. 34 AFM cantilevers were calibrated as described, 35 with the spring constant determined in air (nominal 0.03 N/m, measured values from 0.03 to 0.045 N/m). Fluorescein biotin (Molecular Probes) was used as AFM probe, and was fixed noncovalently with polyethylene glycol (PEG) (molecular range up to 8000, Sigma Chemicals, UK) 36 into the cantilever tip. Determination of the single-moleculereceptor interaction forces was performed as described. 36 Targeting of biotinylated compounds P Lehtolainen et al
